CClinicalTrials.gg
Sign In
Status unknownNCT04963101Updated Jul 15, 2021

RNA-seq Analysis of PBMC in Patients With OPLL

An observational study in OPLL, PBMCs and Transcriptome, sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University · Observational

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

In this study, we planned to identify transcriptome expression profiles (circRNAs, lncRNAs, and mRNAs) from peripheral blood mononuclear cells (PBMCs) of 30 patients with OPLL and 30 other non-OPLL patients by high-throughput sequencing.Sequence analysis was used to predict miRNAs that might bind circRNAs and lncRNAs.Through bioinformatics analysis, competitive endogenous RNAs (cerRNAs), as well as coexpression networks among circRNAs, lncRNAs, miRNAs, and mRNAs, were constructed to provide key molecules and signaling pathways associated with OPLL.

02

Conditions studied

  • OPLL
  • PBMCs
  • Transcriptome
  • Bioinformatics
03

In context

Lead sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 57 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

A total of 30 peripheral blood samples were enrolled in this study, including 15 cases in the OPLL disease group and 15 cases in the non-OPLL control group.

Inclusion criteria

  1. Voluntarily participate in the clinical study and sign the informed consent;
  2. All OPLL patients meet the diagnostic criteria set out in the JOA Clinical Practice Guidelines for Spinal Ligament Osification 2019;
  3. Age ≥18, gender unlimited;
  4. All non-OPLL patients and healthy volunteers have no serious diseases of the heart, lung, brain, liver, kidney and blood system, such as autoimmune diseases, tumors, psychosis, infectious diseases, etc., and have no bad habits or recent history of taking special drugs.

Exclusion criteria

Exclusion Criteria:

  1. Unable to sign the informed consent;
  2. Patients who do not meet the inclusion criteria or diagnostic criteria;
  3. \<18 years old;
  4. Women planning to become pregnant/lactating/pregnant;
  5. Complicated with serious heart, lung, brain, liver, kidney, blood system diseases, such as autoimmune diseases, tumors, mental illness, infectious diseases, drug addiction and other bad addicts;Those who have recently taken special drugs;
  6. Individuals who do not agree to donate peripheral blood or who are obviously uncomfortable with drawing blood.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. circRNA, lncRNA, mRNA

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Facility
    Zhuhai, Guangdong, China
    • Ning Jiang · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04963101
Lead sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Responsible party
Huading Lu (Director of orthopaedics, Fifth Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Jul 15, 2021
Start date
Jun 25, 2021
Primary completion
Jun 25, 2022 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Jul 15, 2021

Study contacts

Ning Jiang, M.D
Contact
jiangn57@mail2.sysu.edu.cn
+86 15653868023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University

Start the discussion